

**CURRICULUM VITAE  
SUMEET KUMAR MENDONCA, MD**

**Private Practice**

**1/01/2012 Ironwood Cancer & Research Centers**  
3645 S. Rome #209, Gilbert, AZ 85297  
480-890-7705

**08/2008 – 12/2011 Desert Oncology Associates**

**Education**

**09/01/1993 – 06/30/1998**

**Bachelor of Medicine and Bachelor of Surgery (M.B.B.S)**

University Of Mumbai, Mahatma Gandhi Mission's Medical College  
Mumbai, India

**08/1990 – 06/1992**

**Undergraduate (Biology Major)**

Indian Language School, Lagos, Nigeria ,Affiliate of the Central Board  
Secondary Education New Delhi, India.(All India Senior School Certificate  
Examination)

**Medical Training**

**07/01/2005-06/30/2008 Fellowship in Hematology-Oncology**

Caritas St. Elizabeth's Medical Center of Boston,  
TUFTS University School Of Medicine

**07/01/2002-06/30/2005 Residency in Internal Medicine**

Caritas St. Elizabeth's Medical Center of Boston,  
TUFTS University School Of Medicine

**06/1999- 06/2000**

**Housemanship:**

Sen Gupta's Hospital, Mumbai, India

**04/1998 - 12/1999**

**Internship:**

Mahatma Gandhi Mission's Medical College, Mumbai, India  
First Referral Unit, Mumbai, India  
(Rotations in medicine, surgery, obstretics/gynecology, casualty medicine,  
pediatrics, ENT, ophthalmology)

**05/1996 – 06/1996 Observer's Post:**

Victoria Island Consultancy and Hospital Services, Department Of Diagnostic  
Radiology, Lagos, Nigeria

**Board Certification**

**American Board Of Internal Medicine – Internal Medicine 08/2005**

**American Board of Internal Medicine – Medical Oncology 10/2008**

**Licensure**

**Arizona Medical Board License #40326**

Expires 6/25/2009

**Massachusetts Board of Registration in Medicine License # 226250**

Expired 6/25/2008

- Professional Membership**
- American Society Of Clinical Oncology**
  - American Society Of Hematology**
  - American Medical Association**
  - Indian Medical Association**
- Professional Appointments** **06/01/2007-06/30/2008**  
Internal Medical Staff ( Hospitalist)-Caritas St Elizabeth's Medical Center of Boston
- Research Experience** **08/2000 – 06/2002 Post-Doctoral Fellow:**  
Research at the Center for Immunotherapy in Cancer and Infectious Diseases, University Of Connecticut Health Center
- Publications**
- A rare case of paradoxical amniotic fluid embolism-A Case Report and Review Of the Literature. Kumar SK, Wong Glenn, Maysky M, Thein Oo (accepted)
- Binder, R.J., Kumar, S.K., Srivastava, P.K. Naturally formed or artificially reconstituted non-covalent alpha2-macroglobulin peptide complexes elicit CD91-dependent cellular immunity (Cancer Immunity, 2002 Dec18;2:16)
- Srivastava, P.K., Kumar, S.K., and Mendonca, C.C. (2001). Principles and practice of the use of heat shock protein-peptide complexes for Immunotherapy of Human Cancer, ( Principles and Practice Of Biologic Therapy Of Cancer, Third Edition, Volume 2)
- Poster Presentation**
- Retrospective analysis of outcomes of patients with acute leukemia receiving induction chemotherapy at Caritas St Elizabeth's Medical Center from 2002 to 2006.
- Glenn Wong, Sumeet Kumar, Thein H Oo. Department of Medicine, Caritas St Elizabeth's Medical Center, TUFTS University School Of Medicine. Presented in at the Annual Research Meeting, March 2006
- Conferences**
- American Society Of Clinical Oncology, Annual Meeting, Chicago, June 2007
- Symposium on Hematological Malignancies, Harvard University, Boston, May 2007
- Investigator Meeting-A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer, Non-Small Cell Lung Cancer or Breast Cancer (ARIES), San Francisco, December 2007
- American Society Of Clinical Oncology 2006 Annual Meeting Updates-New York, July 2006

Emerging Trends in Oncology (Updates from The AACR and ASCO Meetings)- Boston, June 2006

Current Trends in Breast Cancer (Updates from the 2005 San Antonio Breast Cancer Symposium)- Boston, February 2006

Hematology Highlights (by the American School of Oncology and Medical Education Collaborative ) –New York, January 2005

American Society of Hematology-Annual Meeting- Atlanta, December 2005

Best of ASCO (American Society of Clinical Oncology), Boston, 2004

3rd International Conference on Heat Shock Proteins in Immune Response, Connecticut, 2002

2<sup>nd</sup> International Conference on Heat Shock Proteins in Immune Response, Connecticut, 2000

Cancer Vaccines, 2000 (An International Symposium Sponsored by the Cancer Research Institute), New York, 2000

## Honors

### **The Brian Trainor Memorial Award (2005)**

**First Class:** Bachelor of Medicine and Bachelor of Surgery (M.B.B.S) University of Mumbai (December 1998)

**Merit Certificate:** Outstanding academic performance and for being the top 0.1% of successful candidates of All India Senior Secondary School Certificate Examination in Biology, (March 1992)

**General Proficiency Award:** English. Indian Language School, Lagos, Nigeria (March 1992)

**Distinction:** All India Secondary School Examination Indian Language School, Lagos, Nigeria (March 1990)

## Presentations

Advanced Pancreatic Cancer- Where Do We Stand in 2007, February 2007

Cancer Pain- Caritas St. Elizabeth's Medical Center Of Boston, January 2007

Primary Amyloidosis- Caritas St. Elizabeth's Medical Center Of Boston December 2006

Cardiotoxicity Related to Use of Chemotherapeutic Agents- Caritas St. Elizabeth's Medical Center Of Boston, August 2006

Iron Metabolism and Hemochromatosis- Caritas St. Elizabeth's Medical Center Of Boston, May 2006

Hepatocellular Carcinoma-Presentation, Diagnosis and Treatment Options- Caritas St. Elizabeth's Medical Center Of Boston, April 2006

Management Of Locally Advanced Non- Small Cell Lung Cancer- Caritas St. Elizabeth's Medical Center Of Boston, February 2006

American Society Of Hematology Updates on Chronic Myeloid Leukemia- Caritas St. Elizabeth's Medical Center Of Boston, December 2005

Esophageal Cancer-Presentation, Diagnosis and Treatment Options- Caritas St. Elizabeth's Medical Center Of Boston, September 2005

Role of Prostate Specific Antigen in Prostate Cancer Screening. Caritas St. Elizabeth's Medical Center Of Boston ( November 2004)

Febrile Neutropenia. Caritas St. Elizabeth's Medical Center Of Boston ( August 2004)

Skin Manifestations Of Internal Malignancies. Caritas St. Elizabeth's Medical Center Of Boston, TUFTS University. ( October 2003)

Acute Rheumatic Fever. Caritas St. Elizabeth's Medical Center Of Boston, TUFTS University. (June 2003)

Downregulation of CD91 in response to gp96. University of Connecticut Health Center, Farmington, Connecticut (January, 2002)

Pathogenesis & Management of Pre-eclampsia and Eclampsia Mahatma Gandhi Mission's Medical College, Mumbai, India ( February, 1999)

Primary Hyperlipidemia Mahatma Gandhi Mission's Medical College, Mumbai, India ( May 1994)

## Teaching

Physical Diagnosis Workshop for the Northeastern University Physician Assistant Program, Winter Semester 2004.

Physical Diagnosis Workshop for the Northeastern University Physician Assistant Program, Spring Semester 2005.

Emergency Medicine Orientation Program for First and Second Year Medical Students from Tufts School of Medicine (2002-2005)

## Organizational Experience

Team member of the New Mumbai School Health Program (1998-1999)

Active participation in "Polio Eradication By Year 2000 Program" (1998-1999)

## Extracurricular Activities

Swimming:

Gold Survival Award and Certificate of Proficiency in Swimming

Tennis

## Languages

English, Hindi and Punjabi

## Research Protocols: Sub Investigator Responsibilities

**Amgen Protocol 20060136**: A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer. (2007- )

**Astra Zeneca Protocol D4200C00036**: A Phase III, Randomized, Double-Blinded, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of 1<sup>st</sup> Line Anti-Cancer Therapy. (2007 – 2008)

**Amgen Protocol 20060362**: An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer (2008 - )

**Pfizer Protocol A6181104**: A Randomized, Phase 2B Study of Sunitinib Plus Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX as First-Line Treatment In Patients with Metastatic Colorectal Cancer (2008 - )

**Sanofi-Aventis Protocol**: A Multicenter, Randomized, Double-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-Line Treatment of Patients with Metastatic Colorectal Cancer Treated with Oxaliplatin/5-FU/LV (2007 – 2008)

**Novacea Protocol 011-007**: A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2) (2007)

**Abbott Protocol M10-301**: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment (2009- )

**Genentech Protocol TDM4370g/Roche Protocol BO21977**: A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy (EMILIA) (2009- )

**Novartis Protocol CRAD001Y2301**: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole (BOLERO 2). (2009- )

**Novartis Protocol CRAD001J2301**: A Randomize Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO 1). (2009- )

**Imclone Protocol CP12-0606/TRIO-012**: A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of iMC-1121 B Plus Docetaxel versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer. Protocol IMCL CP12-0606/TRIO-012. (2010 –

**Novartis Protocol CRADN2301** : A Randomized Double-Blind, Placebo-Controlled, Multicenter phase III Study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy (**PILLAR 2**) (2010 –

**GlaxoSmith Kline Protocol LPT112515**: A Randomized, Phase III, Open-Label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer (**HALT-MBC**) (2010 –

**Peregrine Protocol PPHM 1001**: A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients with Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (2010 –

**Peregrine Protocol PPHM 0902**: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (2010 -

**Novocure Protocol EF-24/Lunar**: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (LUNAR) (2018- ).

**BeyondSpring Pharmaceuticals Inc. Protocol 450-0001/Dublin-3**: Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3) (2017- ).

**G1 Therapeutics Protocol G1T28-05**: Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer (2017- )

**Pharma Mar Protocol PM1183-C-003-14**: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial) (2016- )

**Eli Lilly and Company Protocol LUN 288/I6A-MC-CBBE**: A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung (2016-2018)

**Hoffmann-La Roche Protocol GO29436**: A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (2015- )

**AstraZeneca Protocol D4191C00004**: A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally

Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) (2014-2018)

**AstraZeneca Protocol D4191C00001:** A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC) (2014-2017)

**Peregrine Protocol PPHM1202:** SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIB/IV Non-Squamous Non Small-Cell Lung Cancer (2014-2017)

### **Breast Cancer Trials**

**Boehringer Ingelheim BI1280-0022:** Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2-metastatic breast cancer and non-visceral disease (2019- )

**Daiichi Sankyo Protocol DS8201-A-U303:** A Phase-3, multicenter randomized, open-label, active-controlled trial of DS-8201A, an anti-her2-antibody drug conjugate (ADC) versus treatment of physician's choice for HER2low, unresectable and/or metastatic breast cancer subjects.(2019 - )

**Daiichi Sankyo Protocol DS8201-A-U301:** A Phase 3, multicenter, randomized, open-label, active-controlled of DS-8201A, an anti-HER2-antibody drug conjugate, versus treatment of investigator's choice for HER2-positive, unresectable and/or metastatic breast cancer subjects pretreated with prior standard of care HER2 therapies, including T-DM1(2019-)

**Novartis Pharmaceuticals Protocol CLAG525B2101:** A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or second line therapy in patients with advanced triple-negative breast cancer (2018-)

**Odonate Therapeutics Protocol ODO-TE-V301:** A Multinational, Multicenter, Randomized, Phase 3 Study of Teseaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

**Merrimack Pharmaceuticals Protocol MM-121-02-02-10/ Sherboc:** Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC) (2018- )

**Macrogenics, Inc. Protocol CP-MGAH22-04:** A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus

Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment (2016-)

**Celgene Corporation Protocol CC-486-BRSTM-001**: A Phase 2, Randomized, Open-label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor (2015-2017)

**Novartis Pharmaceuticals Protocol CLEE011A2404**: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease COMPLEMENT-1 (2017- )

**Novartis Pharmaceuticals Protocol CLEE011XUS29**: A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor (2017-)

**Novartis Pharmaceuticals Protocol CLEE011XUS29**: A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor (2017- )

**Merck Sharp & Dohme Corp. Protocol MK3475-119**: A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119) (2016-2017)

**Novartis Protocol CBYL719C2301A**: Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment (2016-)

**Novartis Protocol CLEE011F2301**: A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment (2015-)

**Eli Lilly Protocol I3Y-MC-JPBM**: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting (2015-)

**Novartis Protocol CLEE011A2301**: A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for



the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease (2014- )

**Pfizer protocol A5481023: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3** Trial Of Fulvestrant (Faslodex (Registered)). With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy (2013- )

**Puma Biotechnology Protocol PUMA-NER-1301:** A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA) (2013- )

**Celgene Corporation Protocol ABI-007-MBC-001:** A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer (2013-2017)

**F. Hoffmann-La Roche Ltd / Genentech Inc Protocol MO27775:** A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer (2012- )

#### **Pancreatic Cancer Trials**

**Incyte Corporation INCB 18424-362:** A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study) (2014-2017)

**Gilead Sciences Protocol GS-US-370-1296:** A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase (2014-2017)

#### **Ovarian Cancer Trials**

**Tesaro, INC. Protocol PR-30-5020-C:** A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (2016-2018)

#### **Prostate Cancer Trials**

**Roche Ltd Protocol CO39303 IPATential150:** Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus

Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATentia150) (2017- )  
**Bayer Healthcare Pharmaceuticals Protocol BAY 1841788 / 17777**: A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer

**Janssen Research & Development, LLC on behalf of Aragon Pharmaceuticals, Inc. Protocol 56021927PCR3003**: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy (ATLAS) (2016- )  
**Sotio a.s. SP005**: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy (2014- )

#### **Colorectal Cancer Trials**

**AbbVie Protocol M14-064**: Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab.(2018- )

#### **Lymphoma Trials**

**Bayer Healthcare Pharmaceuticals Inc., Protocol BAY 80-6946 / 17833**: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-4 (2018- )

**TG Therapeutics, Inc Protocol UTX-TGR-205**: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (2016- )

**Novartis Protocol OFB114612**: A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed after Rituximab Therapy (2011-2017)

**Novartis Protocol CRAD001N2301**: A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy (2010-2016)

#### **Myeloma Trials**

**Merck Sharp & Dohme MK-3475-183-01**: A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without

Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (**KEYNOTE 183**) (2016-)

**Millennium Pharmaceuticals Protocol C16014:** A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma (2013- )

#### **CLL Trials**

**TG Therapeutics Protocol UTX-TGR-304:** A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) (2016- )

**TG Therapeutics Protocol UTX-IB-301:** Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (2015-)

**Genentech Protocol ML29538:** A Phase II, Open-Label Study Of Obinutuzumab Plus Bendamustine (BG) In Patients With Previously Untreated Chronic Lymphocytic Leukemia (2015- )

#### **Melanoma Cancer Trials**

**Merck Sharp & Dohme Corp. Protocol 7902-004:** A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)

**Polynoma LLC Protocol 103A-301:** A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence (2015-)

#### **Head & Neck Cancer Trials**

**Merck Sharp & Dohme Protocol MK-3475-040-10:** A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer (2016- )

#### **Urothelial Carcinoma Trials**

**Merck Sharp & Dohme Corp. Protocol MK3475-361:** A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma (2016- )

#### **Renal Cell Carcinoma Trials**

**Bristol-Myers Squibb Protocol CA 209-920:** Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) (2017- )

**Registry trials**

**Guardant Health Protocol 01-MX-003: GEODE:** Registry of  
Guardant360® Use and Outcomes In People With Advanced Cancer